PMID- 29693155
OWN - NLM
STAT- MEDLINE
DCOM- 20180925
LR  - 20180925
IS  - 1791-2431 (Electronic)
IS  - 1021-335X (Linking)
VI  - 39
IP  - 6
DP  - 2018 Jun
TI  - Assessing stemness and proliferation properties of the newly established colon
      cancer 'stem' cell line, CSC480 and novel approaches to identify dormant cancer
      cells.
PG  - 2881-2891
LID - 10.3892/or.2018.6392 [doi]
AB  - To date two questions that remain unanswered regarding cancer are the following: 
      i) how is it initiated, and ii) what is the role that cancer stem cells (CSCs)
      play in the disease process? Understanding the biology of CSCs and how they are
      generated is pivotal for the development of successful treatment regimens. To
      date, the lack of a representative cell model has prevented the successful
      identification and eradication of CSCs in vivo. The current methods of CSC
      identification are dependent on the protocol used to generate these cells, which 
      has introduced variation and made the identification process more complicated.
      Furthermore, the list of possible markers is increasing in complexity. This is
      further confounded by the fact that there is insufficient information to
      determine whether the cells these markers detect are truly selfrenewing stem
      cells or, instead, progenitor cells. In the present study, we investigated a
      novel cell line model, CSC480, which can be employed to assess CSC markers and
      for testing novel therapeutic regimens. CSC480 cells have been revealed to
      express markers of CSCs such as CD44, ALDH1 and Sox2, that have lower expression 
      in the SW480 cell line. CSC480 cells also expressed higher levels of the cancer
      resistance marker, ABCG2 and had higher proliferative and growth capacity than
      SW480 cells. In the present study, we also evaluated a novel approach to identify
      different cell types present in heterogeneous cancer cell populations according
      to their proliferative ability using the proliferation marker
      5ethynyl2'deoxyuridine (EdU). Furthermore, using EdU, we identified dormant cells
      with a modified labelretaining cell (LRC) protocol. Through this novel LRC
      method, we assessed newly discovered markers of stemness to ascertain their
      capability to identify quiescent from dividing CSCs. In conclusion, the CSC480
      cell line was an important model to be used in unravelling the underlying
      mechanisms that control fastdividing and partially selfrenewing stem cells (SCs) 
      that may give rise to cancer.
FAU - Alowaidi, Faisal
AU  - Alowaidi F
AD  - Department of Pathology and Laboratory Medicine, College of Medicine and
      University Hospitals, King Saud University, Riyadh 11461, Kingdom of Saudi
      Arabia.
FAU - Hashimi, Saeed Mujahid
AU  - Hashimi SM
AD  - Department of Basic Science, Biology Unit, Deanship of Preparatory Year and
      Supporting Studies, Imam Abdulrahman Bin Faisal University, Dammam 34212, Kingdom
      of Saudi Arabia.
FAU - Alqurashi, Naif
AU  - Alqurashi N
AD  - Department of Basic Science, Biology Unit, Deanship of Preparatory Year and
      Supporting Studies, Imam Abdulrahman Bin Faisal University, Dammam 34212, Kingdom
      of Saudi Arabia.
FAU - Alhulais, Reem
AU  - Alhulais R
AD  - Menzies Health Institute Queensland, Griffith University, Gold Coast Campus,
      Queensland 4222, Australia.
FAU - Ivanovski, Saso
AU  - Ivanovski S
AD  - Menzies Health Institute Queensland, Griffith University, Gold Coast Campus,
      Queensland 4222, Australia.
FAU - Bellette, Bernadette
AU  - Bellette B
AD  - Griffith Institute for Drug Discovery, Griffith University, Brisbane, Queensland 
      4111, Australia.
FAU - Meedenyia, Adrian
AU  - Meedenyia A
AD  - Menzies Health Institute Queensland, Griffith University, Gold Coast Campus,
      Queensland 4222, Australia.
FAU - Lam, Alfred
AU  - Lam A
AD  - Menzies Health Institute Queensland, Griffith University, Gold Coast Campus,
      Queensland 4222, Australia.
FAU - Wood, Stephen
AU  - Wood S
AD  - Griffith Institute for Drug Discovery, Griffith University, Brisbane, Queensland 
      4111, Australia.
LA  - eng
PT  - Journal Article
DEP - 20180423
PL  - Greece
TA  - Oncol Rep
JT  - Oncology reports
JID - 9422756
RN  - 0 (Biomarkers, Tumor)
RN  - 0 (CD44 protein, human)
RN  - 0 (Hyaluronan Receptors)
RN  - 0 (Isoenzymes)
RN  - 0 (SOX2 protein, human)
RN  - 0 (SOXB1 Transcription Factors)
RN  - EC 1.2.1.- (aldehyde dehydrogenase 1)
RN  - EC 1.2.1.36 (Retinal Dehydrogenase)
SB  - IM
MH  - Biomarkers, Tumor/*metabolism
MH  - Cell Line, Tumor
MH  - Cell Proliferation
MH  - Colonic Neoplasms/metabolism/*pathology
MH  - *Down-Regulation
MH  - Drug Resistance, Neoplasm
MH  - Gene Expression Regulation, Neoplastic
MH  - Humans
MH  - Hyaluronan Receptors/metabolism
MH  - Isoenzymes/metabolism
MH  - Neoplastic Stem Cells/metabolism/*pathology
MH  - Retinal Dehydrogenase/metabolism
MH  - SOXB1 Transcription Factors/metabolism
MH  - Spheroids, Cellular/cytology/metabolism
EDAT- 2018/04/26 06:00
MHDA- 2018/09/27 06:00
CRDT- 2018/04/26 06:00
PHST- 2017/10/05 00:00 [received]
PHST- 2018/03/07 00:00 [accepted]
PHST- 2018/04/26 06:00 [pubmed]
PHST- 2018/09/27 06:00 [medline]
PHST- 2018/04/26 06:00 [entrez]
AID - 10.3892/or.2018.6392 [doi]
PST - ppublish
SO  - Oncol Rep. 2018 Jun;39(6):2881-2891. doi: 10.3892/or.2018.6392. Epub 2018 Apr 23.